Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Impact of relapse in BDNF receptors expression in patients with a first episode of schizophrenia

  • Bioque, Miquel
  • Llorca-Bofí, Vicent
  • MacDowell, Karina S
  • Amoretti, Sílvia
  • Mezquida, Gisela
  • Cuesta, Manuel J.
  • Díaz-Caneja, Covadonga M.
  • Ibáñez, Ángela
  • Segarra, Rafael
  • González-Pinto, Ana
  • Roldán, Alexandra
  • Sáiz, Pilar A.
  • Mané, Anna
  • Lobo, Antonio
  • Martínez-Pinteño, Albert
  • Cano-Escalera, Guillermo
  • Berrocoso, Esther
  • Bernardo, Miquel
  • 2EPs Group
Background and Hypothesis Relapsing after a first episode of schizophrenia (FES) is a main predictor of clinical and functional prognosis. Brain-derived neurotrophic factor (BDNF) plays a critical role in neuronal development and plasticity, and its signaling may be altered by successive relapses. Design We assessed the impact of first relapse in the expression of the 2 isoforms of the BDNF tropomyosin-related kinase B (TrkB) receptor (active full-length TrkB-F and inactive truncated TrkB-T) in peripheral blood mononuclear cells from 53 FES patients in clinical remission followed up for 3 years. Results The group of participants that relapsed (n = 24) during the follow-up presented a significant decrease in the expression of the active TrkB-F receptor compared to baseline (M = 100 ± 28.13 vs. M = 83.42 ± 33.84, t = 2.5, P = .02), with no changes in the inactive TrkB-T receptor expression nor in BDNF plasma levels. This decrease also led to a significant decline in the F/T ratio (M = 1.13 ± 0.38 vs. 0.94 ± 0.36, t = 2.17, P = .041). No significant differences were found in the receptors’ expression nor in plasma levels in the group of cases that remained in remission (n = 29). These results were not associated with baseline differences between the groups in terms of the BDNF signaling pathway biomarkers, clinical or treatment variables. Conclusions These findings highlight the biological impact that a relapse produces over the systemic BDNF-TrkB signaling pathway, potentially undermining crucial neuronal functions. Identifying the actors involved can help design specific interventions for relapse prevention and improve the functional prognosis of people in the early stages of schizophrenia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix|||0000-0002-2491-200X
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Janssen, Joost|||0000-0001-7613-2067
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Arango, Celso|||0000-0003-3382-4754
  • Vieta, Eduard|||0000-0002-0548-0053
  • Castro-Fornieles, Josefina|||0000-0003-0632-2687
  • Bergé Baquero, Daniel|||0000-0003-2544-1016
  • Albacete, Auria|||0000-0003-4156-4972
  • Giné Serven, Eloi|||0000-0002-3130-5566
  • Parellada, Mara|||0000-0001-7977-3601
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Radua, Joaquim|||0000-0003-1240-5438
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.